Clinical Development Network Across Global Newsroom Participants Member Login Submit an RFP

Solutions · Regulatory Affairs | Global Clinical Regulatory Strategy | Guosa Life Sciences

Navigating Regulatory Pathways with Confidence

Strategic Regulatory Solutions Across the Lifecycle

An effective regulatory strategy is essential to successful clinical development. As environments evolve and global programs grow more complex, sponsors require partners capable of navigating diverse requirements while maintaining compliance, efficiency and scientific integrity.

Submit an RFP

Home/Solutions/Regulatory Affairs | Global Clinical Regulatory Strategy | Guosa Life Sciences

Overview

Strategic Regulatory Solutions Across the Lifecycle

Guosa Life Sciences supports sponsors from early regulatory strategy and clinical trial applications through authority interactions, lifecycle management and market readiness.

Our regulatory professionals develop practical pathways that reduce uncertainty, support timely submissions and facilitate development across multiple jurisdictions.

Regulatory submissions and clinical trial applications

Capabilities

What We Deliver

Strategy and Submissions

Regulatory strategy
Clinical trial applications
Authority submissions
Ethics committee support
Import and export permits

Intelligence and Lifecycle

Regulatory intelligence
Agency interactions
Lifecycle management
Market readiness

The GLS Advantage

Strengthened by the Whole Enterprise

Every solution delivered by Guosa Life Sciences is strengthened by the broader enterprise. Our operational teams are supported by evidence-based Insights, professional development through GLS Academy, collaborative partnerships within the Clinical Development Network and a quality-driven delivery model, enabling scientifically sound, operationally efficient and scalable solutions.

Explore the Enterprise

Evidence-based Insights
GLS Academy development
Clinical Development Network
Integrated quality systems
Technology-enabled delivery
Global operational reach

The capability

What We Actually Do

We prepare, file and steward clinical trial applications through national regulatory authorities and ethics committees in every country in a study. That covers the core dossier and country-specific annexes, translations, investigator and site documentation, import and export permits for investigational product and biological samples, and the responses to authority questions that determine whether a review closes in one cycle or three.

We hold a single regulatory calendar for the program. Each country has its own submission windows and sequencing rules: in some jurisdictions ethics approval must precede the regulatory filing, in others the reverse, and in several the two run in parallel with each requiring evidence of the other's progress. Getting that sequence wrong is the most common cause of a country dropping out of the activation plan, so we map it before the first submission and manage against it through amendments, annual safety reporting, site additions and end-of-trial declarations.

Regulatory considerations

AVAREF joint review and reliance pathways

The most consequential mechanism available in Africa today is AVAREF joint review. A multi-country application submitted through the platform is assessed simultaneously by every participating national authority and ethics committee, with a maximum of 60 days to outcome. The same application filed into a single country on its own can take up to a year. Expedited and emergency pathways run faster still: during a declared public health emergency, joint emergency review has enabled recruitment within 10 to 15 days of application.

Joint review is not automatic. It carries eligibility criteria, a submission format and a coordination burden that falls on the sponsor or its regulatory partner, and applications that arrive incomplete or misaligned across countries revert to sequential national review. Above that sits a continental architecture that is now operational rather than prospective: the African Medicines Agency in Kigali, the handover from the harmonization program at Lusaka in January 2026, and a framework agreement with WHO signed in May 2026. Reliance and work-sharing are moving from pilot to practice, and sponsors who plan for them shorten timelines.

How an engagement runs

The Sequence

1. Regulatory strategy and country assessment

Modeled approval timelines per candidate country, joint review eligibility, and local representation, permit and translation requirements that affect cost and schedule.

2. Dossier build and submission

Core package and country annexes assembled, AVAREF submission coordinated where applicable, national applications filed on the agreed sequence.

3. Question management

Every authority and ethics query tracked centrally, responses coordinated across countries so answers stay consistent, escalation where the activation plan is at risk.

4. Maintenance through close-out

Amendments, safety reporting, site additions and end-of-trial documentation on one calendar.

What you receive

Deliverables

A country-by-country regulatory strategy with modeled timelines. A single submission tracker covering every authority and ethics committee. Consolidated question and response logs. A named regulatory lead accountable for the program.

Evidence and context

The Research Behind This Work

Our operating assumptions are published rather than asserted. The Future of Clinical Trials in Africa sets out why study performance is increasingly determined by ecosystem maturity rather than site selection, and The Untapped Advantage makes the case that institutions, not regions, are the right unit of qualification. Both are available in full, with executive briefs for readers who want the argument in a shorter form.

The Future of Clinical Trials in Africa The Untapped Advantage

Early Development Strategy

Plan the regulatory pathway early.

Explore

Quality Assurance

Inspection readiness.

Explore

Medical Writing

Regulatory documents.

Explore

Insights

Regulatory intelligence.

Explore

FAQ

Common Questions

Which regions do you cover?

We support submissions across multiple jurisdictions, with particular depth in emerging markets including Africa, alongside established FDA, EMA and MHRA pathways.

Do you support the African Medicines Agency landscape?

Yes. Regulatory harmonization across Africa is a core focus area, informed by our Insights platform and regional operational experience.

Let's Discuss Your Program

Tell us about your objectives and our multidisciplinary team will scope an integrated, flexible solution.

Submit an RFP

Navigating Regulatory Pathways with Confidence

Strategic Regulatory Solutions Across the Lifecycle

What We Deliver

Strategy and Submissions

Intelligence and Lifecycle

Strengthened by the Whole Enterprise

What We Actually Do

AVAREF joint review and reliance pathways

The Sequence

1. Regulatory strategy and country assessment

2. Dossier build and submission

3. Question management

4. Maintenance through close-out

Deliverables

The Research Behind This Work

Explore Related Capabilities

Early Development Strategy

Quality Assurance

Medical Writing

Insights

Common Questions

Let's Discuss Your Program